Evommune
Palo Alto, US · Founded 2020 · 9 known investors
Evommune develops therapies targeting the underlying sources of chronic inflammatory diseases, aiming to provide underserved patient populations with more than symptomatic relief. The company runs discovery and development programs with a focus on immunology.
Founders & leadership
Evommune was founded in 2020 by Luis Pena.
LP
Luis PenaFounder
JD
Janice DrewNamed on SEC filing
DC
David CohenNamed on SEC filing
GM
Gregory MossNamed on SEC filing
EB
Eugene BauerNamed on SEC filing
FB
Francois BeaubienNamed on SEC filing
JP
Jeegar PatelNamed on SEC filing
BM
Benjamin McGrawNamed on SEC filing
Board
RH
Robert HopfnerBoard director
DD
FV
Investors · 9
Andera PartnersParis
Avego BioScience CapitalAlpharetta
B Capital GroupManhattan Beach · $10M – $50M
B4 Capital$10M – $50M
Beiersdorf Innovation FundHamburg · $550K – $5.5M
FemHealth VenturesShort Hills
Longwood FundBoston
RA CapitalBostonvia Derek DiRocco · board
EQT Life SciencesreportedLuxembourg · $11M – $66Mvia Felice Verduyn - Van Weegen · board
Competitors · 4
by search overlapImmunome26 shared keywordsImmunome is a clinical-stage oncology company that discovers and develops targeted cancer therapies, with a focus on antibody-drug conjugates (ADCs). Its pipeline includes varegacestat (a gamma secretase inhibitor for desmoid tumors), IM-1021 (a ROR1-targeted ADC), and IM-3050 (a FAP-targeted radioligand), aimed at addressing high unmet need in cancer treatment.
Primmune Therapeutics24 shared keywordsPrimmune Therapeutics develops PRTX007, an orally administered, systemically active TLR7 agonist that activates interferon-associated innate immune pathways for use in cancer immunotherapy. The candidate is being developed for oncology applications, including combination with immune checkpoint inhibitors and neoadjuvant/adjuvant settings, and has been tested in two Phase 1 studies in healthy volunteers.
NexImmune22 shared keywordsNexImmune is a biotechnology company developing antigen-directed immunotherapies based on its proprietary AIM nanoparticle platform, which mimics dendritic cell signaling to activate antigen-specific T cell responses. Its programs target oncology, autoimmune disorders, and infectious disease using formats including adoptive cell therapy (AIM ACT) and direct injection (AIM INJ).
Inimmune21 shared keywordsInimmune is a clinical-stage biotech company that discovers and develops immunotherapies based on innate immune modulation, including Toll-like receptor agonists, to treat inflammatory conditions such as allergy, cancer, and autoimmune disease. Its lead program, INI-2004, is an intranasal TLR4 agonist in Phase 2 trials for allergic rhinitis, alongside INI-4001, a TLR7/8 agonist in Phase 1 oncology trials, plus pre-clinical vaccine adjuvant work.
Companies competing with Evommune for the same Google search keywords, organic and paid, via search-intersection analysis.
Funding
SEC filings, press & company announcements$267.3M disclosed across 4 of 5 rounds · 2020–2026
- Undisclosed amountprivate placementFeb 2026Source ↗
▶$57.5MraisedJan 2025 · 16 investors · OtherRule 506(b)
▶$57.5MraisedJan 2025 · 16 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Felice Verduyn-van WeegenDirector
- Janice DrewExecutive Officer
- Benjamin McGrawDirector
- Eugene BauerExecutive Officer, Director
- Derek DiRoccoDirector
- Luis PenaExecutive Officer, Director
- Kyle CarverExecutive Officer
- Gregory MossExecutive Officer
- Jeegar PatelExecutive Officer
- David CohenDirector
- Robert HopfnerDirector
- Francois BeaubienDirector
- Yuexin YuDirector
- Offering amount
- $57.5M
- Amount sold
- $57.5M
- First sale
- Mar 2023
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$81.8MraisedJan 2025 · 10 investors · OtherRule 506(b)
▶$81.8MraisedJan 2025 · 10 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Janice DrewExecutive Officer
- David CohenDirector
- Robert HopfnerDirector
- Derek DiRoccoDirector
- Gregory MossExecutive Officer
- Eugene BauerExecutive Officer, Director
- Felice Verduyn-van WeegenDirector
- Francois BeaubienDirector
- Jeegar PatelExecutive Officer
- Yuexin YuDirector
- Benjamin McGrawDirector
- Luis PenaExecutive Officer, Director
- Kyle CarverExecutive Officer
- Offering amount
- $84.4M
- Amount sold
- $81.8M
- First sale
- Aug 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$115.5MraisedJan 2025 · 25 investors · OtherRule 506(b)
▶$115.5MraisedJan 2025 · 25 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Derek DiRoccoDirector
- Eugene BauerExecutive Officer, Director
- Felice Verduyn-van WeegenDirector
- Robert HopfnerDirector
- Kyle CarverExecutive Officer
- David CohenDirector
- Gregory MossExecutive Officer
- Francois BeaubienDirector
- Benjamin McGrawDirector
- Jeegar PatelExecutive Officer
- Yuexin YuDirector
- Janice DrewExecutive Officer
- Luis PenaExecutive Officer, Director
- Offering amount
- $115.5M
- Amount sold
- $115.5M
- First sale
- Oct 2024
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$12.5MraisedJan 2025 · 18 investors · OtherRule 506(b)
▶$12.5MraisedJan 2025 · 18 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Eugene BauerExecutive Officer, Director
- Felice Verduyn-van WeegenDirector
- Gregory MossExecutive Officer
- Yuexin YuDirector
- Jeegar PatelExecutive Officer
- Francois BeaubienDirector
- Robert HopfnerDirector
- Kyle CarverExecutive Officer
- Luis PenaExecutive Officer, Director
- David CohenDirector
- Derek DiRoccoDirector
- Benjamin McGrawDirector
- Janice DrewExecutive Officer
- Offering amount
- $12.5M
- Amount sold
- $12.5M
- First sale
- Jun 2020
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Evommune Q2 Earnings: $32.2M Net Loss, Trial Data Due | EVMN Stock Newsstocktitan.net · Aug 2026Frequently asked questions
- What does Evommune do?
- Evommune develops therapies targeting the underlying sources of chronic inflammatory diseases, aiming to provide underserved patient populations with more than symptomatic relief. The company runs discovery and development programs with a focus on immunology.
- Who founded Evommune?
- Evommune was founded by Luis Pena in 2020.
- Who are Evommune's investors?
- Evommune's investors include Andera Partners, Avego BioScience Capital, B Capital Group, B4 Capital, Beiersdorf Innovation Fund, FemHealth Ventures, Longwood Fund, RA Capital and 1 more.
- How much funding has Evommune raised?
- Evommune has disclosed $267.3M raised across 4 of its 5 known rounds.
- Where is Evommune headquartered?
- Evommune is headquartered in Palo Alto, US.